Advertisement
Advertisement
ACAD
Acadia Pharmaceuticals Inc.
21.32
USDSponsored
+0.37
+1.77%
May 21, 16:00 UTC -4
Closed
After-Market
21.32
0.00
+0.02%
ACAD Earnings Reports
Positive Surprise Ratio
ACAD beat 27 of 42 last estimates.
64%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$302.57M
/$0.06
Implied change from Q1 26 (Revenue/ EPS)
+12.87%
/+200.00%
Implied change from Q2 25 (Revenue/ EPS)
+14.37%
/-62.50%
Acadia Pharmaceuticals Inc. earnings per share and revenue
On May 06, 2026, ACAD reported earnings of 0.02 USD per share (EPS) for Q1 26, missing the estimate of 0.06 USD, resulting in a -68.40% surprise. Revenue reached 268.06 million, compared to an expected 286.32 million, with a -6.38% difference. The market reacted with a +5.03% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.06 USD, with revenue projected to reach 302.57 million USD, implying an increase of 200.00% EPS, and increase of 12.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Acadia Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Acadia Pharmaceuticals Inc. reported EPS of $0.02, missing estimates by -68.4%, and revenue of $268.06M, -6.38% below expectations.
How did the market react to Acadia Pharmaceuticals Inc.'s Q1 2026 earnings?
The stock price moved up 5.03%, changed from $21.48 before the earnings release to $22.56 the day after.
When is Acadia Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Acadia Pharmaceuticals Inc.'s next earnings report?
Based on 7
analysts, Acadia Pharmaceuticals Inc. is expected to report EPS of $0.06 and revenue of $302.57M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement